KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Research & Development (2017 - 2026)

Elanco Animal Health's Research & Development history spans 9 years, with the latest figure at $93.0 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 14.81% to $93.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $368.0 million, a 6.98% increase, with the full-year FY2025 number at $368.0 million, up 6.98% from a year prior.
  • Research & Development hit $93.0 million in Q4 2025 for Elanco Animal Health, up from $89.0 million in the prior quarter.
  • Over the last five years, Research & Development for ELAN hit a ceiling of $94.0 million in Q2 2021 and a floor of $78.0 million in Q3 2022.
  • Historically, Research & Development has averaged $86.4 million across 5 years, with a median of $87.0 million in 2024.
  • The widest YoY moves for Research & Development: up 59.32% in 2021, down 20.0% in 2021.
  • Tracing ELAN's Research & Development over 5 years: stood at $92.0 million in 2021, then fell by 13.04% to $80.0 million in 2022, then decreased by 1.25% to $79.0 million in 2023, then rose by 2.53% to $81.0 million in 2024, then grew by 14.81% to $93.0 million in 2025.
  • Business Quant data shows Research & Development for ELAN at $93.0 million in Q4 2025, $89.0 million in Q3 2025, and $92.0 million in Q2 2025.